Stock of the Day

July 26, 2019

Mirum Pharmaceuticals (MIRM)

$82.39
+$2.43 (+3.0%)
Market Cap: $5.19B

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Today's Trend

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is receiving mixed investor signals. Positive clinical news and a bullish Citi outlook are being offset by broad reductions to HC Wainwright’s earnings forecasts, which may explain recent pressure on the shares.

  • Mirum’s Livmarli achieved the primary goal of the Phase III EXPAND study in ultra-rare liver diseases, improving cholestatic itching and reducing serum bile acids. The company plans to submit the data to the FDA in 2027, potentially expanding Livmarli’s addressable market. Mirum’s Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
  • Citigroup reportedly sees substantial upside potential for MIRM, reinforcing the longer-term investment case. Citigroup Forecasts Strong Price Appreciation for Mirum Pharmaceuticals
  • HC Wainwright maintained its Buy rating and $200 price target, well above the stock’s recent trading level. However, the firm lowered its FY2027 EPS forecast to $1.16 from $1.42 and reduced estimates for Q3 2026, Q1 2027, Q2 2027 and Q4 2027. The changes suggest continued confidence in Mirum’s long-term opportunity but a more cautious view of near-term earnings.
  • The repeated earnings-estimate cuts could weigh on the stock because they reduce projected profitability and may signal slower-than-expected commercialization, expenses, or revenue growth. Investors may focus on whether Mirum can convert Livmarli’s clinical progress into stronger financial results.
← Previous Stock of the DayNext Stock of the Day →

Recent News